CLAIM CARD
Quantitative findings from this network meta-analysis revealed a differential safety signal across SGLT2 inhibitor agents. This effect estimate suggests a meaningfully elevated gastrointestinal risk that distinguishes canagliflozin from other agents within the class. The agent-specific nature of this finding underscores that pharmacokinetic and pharmacodynamic differences among SGLT2 inhibitors translate into clinically distinct safety profiles, even within the same mechanistic class.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025